Xin Lang Cai Jing·2026-02-03 01:36Core Viewpoint - Haohai Biological Technology Co., Ltd. is experiencing a decline in revenue and net profit, with significant changes in shareholder structure and financing activities [2][3]. Group 1: Financial Performance - For the period from January to September 2025, Haohai Biological reported operating revenue of 1.899 billion yuan, a year-on-year decrease of 8.47% [2]. - The net profit attributable to shareholders for the same period was 305 million yuan, reflecting a year-on-year decline of 10.63% [2]. Group 2: Shareholder and Financing Activities - As of February 2, 2025, the number of shareholders increased to 8,388, representing a 7.44% rise compared to the previous period [2]. - On February 2, 2025, Haohai Biological had a financing balance of 113 million yuan, accounting for 1.28% of its market capitalization, which is above the 50th percentile level over the past year [1]. - The company has cumulatively distributed dividends of 891 million yuan since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Business Overview - Haohai Biological, established on January 24, 2007, and listed on October 30, 2019, focuses on the research, production, and sales of medical devices and pharmaceuticals [1]. - The revenue composition of the company includes 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [1].